NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoHealth, Inc. (NASDAQ: GOCO), Semler Scientific Inc. (NASDAQ: SMLR), Fulgent Genetics, Inc. (NASDAQ: FLGT), and Abacus Global Management, Inc. (NASDAQ: ABL). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Semler Scientific Inc. (NASDAQ: SMLR)
On February 28, 2025, Semler filed its Form 10-K with the SEC and therein, disclosed that the Company received an initial civil investigative demand from the U.S. Department of Justice ("DOJ") in July 2017 regarding Semler's claims for reimbursement related to its QuantaFlo device. Semler received subsequent requests for information in February 2019, December 2021, April 2022, and April 2023. In February 2025, Semler participated in settlement discussions with the DOJ, which were unsuccessful. The Company disclosed that "there is a risk that DOJ will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages." On this news, the price of Semler shares declined by $4.03 per share, from $42.92 per share on February 28, 2025, to close at $38.89 on March 3, 2025.
For more information on the Semler investigation go to: https://bespc.com/cases/SMLR
GoHealth, Inc. (NASDAQ: GOCO)
On May 1, 2025, the U.S. Department of Justice ("DOJ") announced the filing of a False Claims Act complaint against several health insurance companies and insurance broker organizations, including GoHealth, "alleging that from 2016 through at least 2021, the defendant insurers paid hundreds of millions of dollars in illegal kickbacks to the defendant brokers in exchange for enrollments into the insurers' Medicare Advantage plans."
On news of the DOJ's lawsuit, GoHealth's stock price fell $1.09 per share, or 10.35%, to close at $9.44 per share on May 1, 2025.
For more information on the GoHealth investigation go to: https://bespc.com/cases/GOCO
Abacus Global Management, Inc. (NASDAQ: ABL)
On June 4, 2025, Morpheus Research published a report titled "Abacus Global Management: This $740 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue By Systematically Underestimating When People Will Die." On this news, Abacus Global's stock price fell more than 21%.
For more information on the Abacus investigation go to: https://bespc.com/cases/ABL
Fulgent Genetics, Inc. (NASDAQ: FLGT)
On February 28, 2025, Fulgent disclosed in its annual report, filed with the U.S. Securities and Exchange Commission, that it had received a civil investigative demand from the U.S. Department of Justice regarding potential false claims submitted under the Uninsured Program.
On this news, Fulgent's stock price fell $0.41 per share, or 2.61%, over the following two trading sessions, to close at $15.28 per share on March 3, 2025.
For more information on the Fulgent investigation go to: https://bespc.com/cases/FLGT
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
